Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SYT9 antisense RNA 1 (SYT9-AS1), also known as CTD-2516F10.2, is a long non-coding RNA transcribed antisense to the synaptotagmin 9 (SYT9) gene locus. Its molecular function, biology, and disease relevance remain largely uncharacterized in public research and molecular databases. Unlike the protein-coding SYT9, which is involved in calcium-dependent vesicular trafficking and neurotransmitter release in select brain regions[1][2][3], SYT9-AS1 has no established therapeutic or biomarker relevance. It is catalogued as a lncRNA by genome annotation resources but has not been directly studied as a drug target, disease biomarker, or in safety evaluations. Note: SYT9-AS1 should not be confused with SYT9, the protein-coding gene encoding synaptotagmin 9, which is studied for its role in neuronal exocytosis, synaptic transmission, and potential roles in neurological function and disorders[1][2][3]. No known drugs, mechanisms, or biomarkers involve SYT9-AS1, and current scientific evidence does not support therapeutic targeting or functional studies of this antisense RNA.
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SYT9 antisense RNA 1 (SYT9-AS1).